The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Phase 2 data highlight tolerability issues at higher VK2735 doses, suggesting real-world efficacy may be limited by discontinuation rates. Viking's induction-maintenance strategy appears reactive, with competitors like Amgen and Pfizer advancing superior, longer-acting regimens. With $700M in cash and no major partner, VKTX risks being squeezed in a crowded, price-competitive obesity market. Getty Images Overview My last glance at Viking Therapeutics, Inc. ( VKTX ) was in August—I was a Sell on the stock. This is a clinical-stage biotechnology company developing an oral and subcutaneous GLP-1/GIP—basically a “me-too” Eli Lilly ( LLY ) ZEPBOUND. I This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026PR Newswire
- 2 Biotech Stocks Set to Rebound in 2026 [Yahoo! Finance]Yahoo! Finance
- Why Viking Therapeutics (VKTX) Is Down 6.5% After Publishing VK2735 Phase 2 Obesity Trial Results And What's Next [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline [Yahoo! Finance]Yahoo! Finance
- The Best Stocks to Invest $40 in to Start the New Year Off Right [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Analyst Actions
- 11/12/25 - Canaccord Genuity
VKTX
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/5/26 - Form 4
- VKTX's page on the SEC website